engaruh Ekstrak Patikan Kebo (Euphorbia hirta L.) terhadap Hitung Eosinofil Darah Tepi pada Mencit Model Asma Alergi
Authors
-
Diding Heri Prasetyo
Biochemistry Laboratory, School of Medicine, Immunology Division, Biomedical Laboratory School of Medicine, Sebelas Maret University,
Surakarta
-
R.P. Andri Putranto
Biochemistry Laboratory, School of Medicine, Sebelas Maret University, Surakarta
-
Martini Martini
Biochemistry Laboratory, School of Medicine, Sebelas Maret University, Surakarta
-
Sarsono Sarsono
Biochemistry Laboratory, School of Medicine, Sebelas Maret University, Surakarta
Keywords:
cytokines, lipid mediators, pharmacological activities, Euphorbia hirta L.Abstract
Asthma is characterized by both chronic inflammation and remodeling of the airways. Eosinophils may contribute to inflammation associated with bronchial asthma by causing tissue damage and subsequently organ dysfunction, but also by the generation of cytokines and lipid mediators. It was reported in previous studies that pharmacological activities were identified in various compounds extracted fromEuphorbia hirta L. such as antiinflammatory,
histamine inhibitor, lipoxygenase inhibitor, anti-allergic and cyclooxygenase inhibitor. This study was aimed to determine the effect of E. hirtaextract onperipheral blood eosinophils count in mice model of allergic asthma. MaleBalb/C mice were sensitized and challenged intraperitoneally (i.p) with ovalbumin(OVA). Mice were immunized i.p. on days 1 and 14 with 2.5 mgof OVA adsorbed to 7.75ml of Aluminium hydroxide gel. OVA challenges (10 mgOVA in l ml of PBS) were administered aerosolly on days 21, 23, 25 and 27, andperipheral blood eosinophilscount was determinedon day 28.A one-way analysis of variance (ANOVA) with LSDpost hocanalysis was used to determine significant differences. Results were expressed as mean+SEM, and values of p<0.05wereconsidered statistically significant. The results showed thatperipheral blood eosinophilscountin the OVA group was51.0+10.4cells/mm E. hirtaextract dose 500 mg/BW/day was30.2+6.3cells/mm3,E. hirtaextract dose 1,000 mg/BW/day was 30.4+6.0cells/mm and antihistamine group was32.2+8.6cells/mm respectively, whilecontrol mice showed46.6-8.8 cells/mm3. It was concluded that E. hirta extract could minimizeperipheralblood eosinophilscount.
References
Blease K, Lukacs NW, Hogaboam CM and Kunkel SL 2000. Chemokines and their role in airway hyperreactivity.Respir Res.; 1(1): 54–61.
Broide DH 2008. Immunologic and inflammatory mechanisms that drive asthma progression to remodeling. J Allergy Clin Immunol. 121(3):560–
Caramori G, Groneberg D, Ito K, Casolari P, Adcock IM and Papi A 2008. New drugs targeting Th2 lymphocytes in asthma. Journal of Occupational Medicine and Toxicology,3(Suppl 1):S6.
Duke JA 2009. List of Chemicals ofEuphorbia hirta L. In: Phyto-chemical and Ethnobotanical Databases. http://www.natrindex.com/duke_plant-G.html
Elias JA, Lee CG, Zheng T, Ma B, Homer RJ and Zhu Z 2003. New insights into the pathogenesis of asthma.J Clin Invest. 111(3): 291–297.
Hammad H and Lambrecht BN 2008. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma. Nature Rev.Immunol. 8: 193204.
Herrick CA and Bottomly K 2003. To Respond Or Not To Respond: T Cells In Allergic Asma. Nature Reviews Immunology 3: 405-412.
Holgate ST and Polosa R 2008. Treatment strategies for allergy and asthma. Nature Rev.Immunol. 8: 218-230.
IPTEKnet 2009. Patikan Kebo(Euphorbia hirta, Linn.) dalam Tanaman Obat Indonesia. http://www.iptek.net.id/ind/pd_tanobat/view.php?mn
u=2&id=19
Jacobsen EA, Taranova AG, Lee NA and Lee JJ 2007. Eosinophils: singularly destructive eff ector cells or purveyors of immunoregulation? J. Allergy Clin. Immunol.119: 1313–1320.
Laprise C, Sladek R, Ponton A, Bernier MC, Hudson TJ and Laviolette M 2004. Functional classes of bronchial mucosa genes that are differentially expressed in asthma.BMC Genomics.; 5: 21.
Lee KS, Lee HK, Hayflick JS, Lee YC, Puri KD 2006. Inhibition of phosphoinositide 3-kinase attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J.20, 455–465.
Mauad T, Bel EH, Sterk PJ 2007. Asthma therapy and airway remodeling. Journal of Allergy and Clinical Immunology.120: 997–1009.
RohS-S, Kim S-H, Lee Y-C and Seo Y-B 2008. Effects of Radix Adenophorae and Cyclosporine A on an OVA-Induced Murine Model of Asthma by Suppressing to T Cells Activity, Eosinophilia, and Bronchial Hyper-responsiveness. Mediators of Inflammation, Article ID 781425, 11 pages.
Shi HZ 2004. Eosinophils function as antigenpresenting cells.J. Leukoc.
Biol.76: 520–527.
Simon D and Simon H 2007. Eosinophilic disorders. J Allergy Clin Immunol. 119 (6):1291-300.
Singh GD, Kaiser P, Youssouf MS, Singh S, Khajuria A, Koul A, Bani S, Kapahi BK, Satti NK, Suri KA, Johri RK 2006. Inhibition of early and late phase allergic reactions byEuphorbia hirta L.Phytotherapy Research.Volume 20 Issue 4,Pages316–321.
Wang H-B, Ghiran I, Matthaei K and Weller PF 2007. Airway Eosinophils: Allergic Inflammation Recruited Professional Antigen-Presenting Cells. The Journal of Immunology,179:7585–7592.
